FDA officials disagree on safety of angiotensin receptor blockersBMJ 2013; 346 doi: https://doi.org/10.1136/bmj.f3730 (Published 07 June 2013) Cite this as: BMJ 2013;346:f3730
- Mike McCarthy
Top officials at the US Food and Drug Administration and a senior safety reviewer have been quarreling over whether there is sufficient evidence to link angiotensin receptor blockers (ARBs) with an increased risk of lung cancer, the Wall Street Journal has reported.1
Internal documents reviewed by the newspaper show that Thomas A Marciniak, medical team leader in the division of cardiovascular and renal products in the FDA’s Center for Drug Evaluation and Research, has called on the agency to issue stronger warnings on the popular drugs, citing a review he conducted that found a 24% increase in the risk of lung cancer in patients who take ARBs.
“The FDA needs to inform patients and physicians about the ARB lung-cancer …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial